December 1, 2021 - Non-regulatory SynAct Pharma strengthens its patent portfolio for AP1189 following an Intention to Grant from the European Patent Office
November 19, 2021 - Non-regulatory SynAct Pharma announces Nomination Committee in respect of AGM 2022
November 11, 2021 - Non-regulatory SynAct Pharma takes advantage of new toxicology results and new tablet formulation to re-design and optimize the study programme with AP1189 in Nephrotic Syndrome
